It's always a nice surprise to see that a company you're invested in is making good on its opportunities and planning to grow on your behalf. In that vein, at the 2024 meeting of the American Society of Clinical Oncology (ASCO) on May 31, Iovance Biotherapeutics (IOVA 0.58%) offered some news that should please its shareholders and perhaps motivate them to buy more of the stock in the near term. To appreciate what it disclosed and why it matters, let's start by putting the new findings into the appropriate ...

SAN CARLOS, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following conferences and events: The live and archived webcasts will be available at https://ir.iovance.com/news-events/events-presentations. About Iovance Biotherapeutics, Inc. Iovance ...

SAN CARLOS, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following conferences and events: The live and archived webcasts will be available at https://ir.iovance.com/news-events/events-presentations. About Iovance Biotherapeutics, Inc. Iovance ...

Iovance Biotherapeutics (IOVA) announced updated clinical results from a cohort of the phase II IOV-COM- 202 study evaluating the combination of its recently approved cell therapy Amtagvi and Merck's blockbuster oncology drug Keytruda in frontline advanced melanoma. Based on a recent data cut that included 23 patients, treatment with the Amtagvi/Keytruda combo achieved a confirmed objective response rate (ORR) of 65.2%, including a complete responses (CR) rate of 30.4%. Management noted that 'nearly all' re ...

SAN CARLOS, Calif., May 17, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ("TIL") therapies for patients with cancer, today announced that on May 16, 2024 (the "Date of Grant"), the Company approved the grant of inducement stock options covering an aggregate of 153,930 shares of Iovance's common stock to thirty new, non-executive emplo ...

Investors are misunderstanding when the biopharma company's flagship drug will begin generating meaningful reportable revenue.Iovance Biotherapeutics (IOVA -19.07%) shares are down to the tune of 18% today following Thursday evening's release of its first-quarter numbers. The sell-off clearly suggests investors didn't like everything they heard. The knee-jerk response to the news, however, looks past a critical detail regarding the report.An irrelevant quarterly reportIovance Biotherapeutics did $715,000 wo ...

Iovance Biotherapeutics, Inc. (IOVA) incurred a loss of 42 cents per share in first-quarter 2024, narrower than the Zacks Consensus Estimate of a loss of 45 cents. In the year-ago quarter, the company reported a loss of 50 cents.During the quarter, the company generated total revenues of $0.7 million — entirely from product sales of its recently-acquired interleukin-2 (IL-2) product Proleukin (aldesleukin). The reported sales missed the Zacks Consensus Estimate of $2.9 million. In the year-ago quarter, Iova ...

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q1 2024 Results Conference Call May 9, 2024 4:30 PM ET Company Participants Sara Pellegrino - Senior Vice President, Investor Relations & Corporate Communications Dr. Fred Vogt - Interim President & Chief Executive Officer Jim Ziegler - Executive Vice President, Commercial Dr. Igor Bilinsky - Chief Operating Officer Jean-Marc Bellemin - Chief Financial Officer Dr. Friedrich Finckenstein - Chief Medical Officer Dr. Brian Gastman - Executive Vice President, Medical ...

For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-36860 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 IOVANCE BIOTHERAPEUTICS, INC. (Exact name of issuer as specified in its charter) (State or other jurisdiction of (I. ...

Exhibit 99.1 Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates Strong Momentum for Amtagvi™ (Lifileucel) U.S. Launch Following U.S. Food and Drug Administration (FDA) Approval 100+ Amtagvi Patients Enrolled Across More Than 40 Current Authorized Treatment Centers (ATCs), with ~50 Total ATCs On Track by End of May and 70+ Total ATCs by Year-End 2024 Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer of Iovance, stated, "The first quarter of 202 ...